Table. Recommendations for immunisation of infants and children aged <2 years using meningococcal ACWY vaccines, by age and vaccine brand
Medical conditions are specified in List. Specified medical conditions associated with increased risk of invasive meningococcal disease.
|
Age at start of vaccine course |
MenACWY vaccine brand |
Dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease) |
|
6 weeks to 5 months |
Menveoa Nimenrix |
3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age) |
|
6–8 months |
Menveo Nimenrix |
2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later) |
|
9–11 months |
Menveo Nimenrix Menactra |
2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later) |
|
12–23 months |
Menveo |
2 doses (8 weeks between doses) |
|
Nimenrix |
1 dose |
|
|
Menactra |
2 doses (8 weeks between doses) |
a. For optimal protection against serogroup A, an extra primary dose (ie a 3+1 schedule) of Menveo should be considered for infants aged <6 months, if travelling to areas where meningococcal A disease is common
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/resources/handbook-tables/table-recommendations-for-immunisation-of-infants-and-children-aged.